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ABSTRACT 
 
Here we describe in more depth the previously published application of the fluorescent probe 4,5-diaminofluorescein (DAF-2) in order 
to reliably measure low levels of nitric oxide (NO) as released from human endothelial cells in vitro. The used approach is based on the 
following considerations a) use low concentrations of DAF-2 (0.1 µM) in order to reduce the contribution of DAF-2 auto-fluorescence 
to the measured total fluorescence, and b) subtract the DAF-2 auto-fluorescence from the measured total fluorescence. The advantage 
of this method is the reliable quantification of NO in a biological system in the nanomolar range once thoroughly validated. Here we 
focus in addition to the previous publication (Leikert et al., FEBS Lett 2001, 506:131-134) on aspects of validation procedures as well as 
limitations and pitfalls of this method. 
 
 
INTRODUCTION 
 
Due to its pivotal biological activities nitric oxide (NO) is a 
molecule of high interest. It is produced as a free radical by 
different isoforms of the enzyme nitric oxide synthase (NOS). 
These enzymes produce NO by catalyzing the oxidation of a 
guanidino nitrogen of L­arginine, thereby converting L-arginine 
to L­citrulline. NO-synthases are either constitutively expressed 
or are induced e.g. by cytokines during inflammation. The 
inducible NO-synthase (iNOS, NOS II) produces NO in the 
nano- up to the micromolar range. Constitutive NO-synthases 
(cNOS), in contrast, such as the endothelial NO-synthase 
(eNOS, NOS III) or the neuronal NO-synthase (nNOS, NOS I) 
produce NO in pico- up to nanomolar concentrations (1, 2).  
 
NO is involved in various physiological, as well as 
pathophysiological processes, such as neurotransmission, the 
immune defence and the maintenance of the vascular 
homeostasis (1, 3-7). Thus, reliable quantification of NO in 
various biological systems is highly desired by scientists in applied 
as well as in basic medical research. 
 
Quantification of NO produced by the constitutive isoforms of 
NOS is, however, challenging due to the low output of NO. To 
handle these problems, different approaches were taken during 
the last few years (8), each with its specific assets and drawback. 
Major drawbacks of most methods are the lack of specificity for 
NO or the low sensitivity that does not allow the detection of 
NO released from cNOS-systems. In addition, often the 
expenses for material, instruments or even know-how (e.g. ESR-
specialist) are too high for an average biomedical laboratory. The 
ideal method should be 1) able to detect low levels of NO as e.g. 
derived from endothelial cells, 2) easy to handle, 3) and not 
require specific equipment that is normally not available in a 
biomedical laboratory. The approach that comes close to these 
requirements is the use of fluorescence probes (9-17). The most 
common probe is 4,5-diaminofluorescein, DAF-2, a fluorescein 
derivative. DAF-2 reacts with an oxidation product of NO to the 
highly fluorescent triazolofluorescein DAF-2T by a known 
reaction mechanism (12, 15, 18). The probe is used to measure 
NO extracellularly (13-17). Although the fluorescence probe 
DAF-2 is commercially available its use is by far not as prevalent 
as could be assumed from the amount of research going on in the 
field of nitric oxide. This was the reason why we recently put 
much effort into this method in order to validate its reliable use 
to detect low levels of NO as released from cNOS systems (19): 
First, we lowered the DAF-2 concentration to 0.1 µM in order to 
limit DAF-2 auto-fluorescence. In addition, we subtracted the 
DAF-2 auto-fluorescence from the total measured fluorescence. 
Due to several inquiries we focus here in more detail on aspects 
of validation procedures as well as on limitations and pitfalls of 
this method. We also provide a detailed experimental protocol. Räthel et al.    
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MATERIALS AND METHODS 
 
Chemicals 
 
DAF-2, DAF-2T, the calcium ionophore A23187 and the NO 
donor MAHMA•NONOate (NOC-9) were purchased from 
Alexis® Biochemicals (Grünberg, Germany). L-arginine 
hydrochloride, dimethylsulfoxide, Superoxide dimutase-
polyethylene glycol-coupled (PEG:SOD) and horseradish 
peroxidase were purchased from Sigma (Deisenhofen, Germany). 
Mn TBAP was purchased from OXIS Research (Portland, USA).  
 
Cell culture 
 
The human endothelial cell line EA.hy 926 (kindly provided by 
Dr. Edgell, University of North Carolina, NC, USA) (20) was 
cultivated as described (19). For experiments, cells were seeded in 
six-well plates at a density of 0.4 x 106 cells per well. Assays were 
performed exactly 4 days after seeding to ensure equal cell 
growth conditions for all experiments.  
 
Spectrofluorimetric determination of NO 
released from endothelial cells 
 
Cells were treated as described in (19). Then, the fluorescence of 
supernatants was measured at room temperature using a 
spectrofluorimeter (RF 1501, Shimadzu) with excitation 
wavelength set at 495 nm and emission wavelength at 515 nm. 
The bandwidth was 10 nm for excitation and for emission. The 
sensitivity was programmed on high (see also Protocols section). 
 
Data analysis 
 
Analysis of data (column statistic, linear regression, statistical 
analysis) was performed using the software GraphPad PRISM® 
(Graph Pad Software, inc., San Diego, CA, USA). 
 
RESULTS AND DISCUSSION 
 
Why using DAF-2 < 1 µM and subtracting the 
auto-fluorescence background? 
 
DAF-2, the fluorescent probe, and DAF-2T, the reaction 
product formed from DAF-2 and NO in the presence of O2 (15, 
21), have an almost identical absorbance maximum and a nearly 
identical emission maximum as well. They, however, differ 
strongly in their fluorescence intensity. The quantum yield of the 
DAF-2T fluorescence is more than 180-fold higher than that of 
DAF-2 (13, 15). Nevertheless, when the fluorescence of DAF-2T 
is detected, the fluorescence of DAF-2 is measured as 
background as well. As a consequence, in NO high-output 
systems the auto-fluorescence of DAF-2 is negligible since 
enough DAF-2 is converted to the high fluorescent DAF-2T. In 
systems with a low output of NO, however, low concentrations 
of formed DAF-2T may not be separable from the high DAF-2 
auto-fluorescence background.  
 
These theoretic considerations were demonstrated 
experimentally, as shown in Figure 1: We employed increasing 
concentrations of DAF-2 (0.01-5 µM in PBS) to either a blank 
vial (no NO source) or to A23187-activated human endothelial 
EA.hy926 cells (low-output NO source) followed by fluorescence 
measurement (λex 495 nm, λem 515 nm). Figure 1 shows that the 
fluorescence intensity obtained from DAF-2/DAF-2T in the 
supernatants of NO-producing endothelial cells does not exceed 
significantly the level of the fluorescence intensity obtained from 
DAF-2 auto-flourescence (no NO source) when concentrations 
o f  D A F - 2  >  1  µ M  w e r e  e m p l o y e d .  T h i s  s u g g e s t s  t h a t  
concentrations < 1 µM DAF-2 should be employed measuring 
NO released from cNOS systems. 
 
In order to proof that concentrations < 1 µM DAF-2 are 
sufficient to trap all NO released from endothelial cells and that 
the correlation between NO concentration and measured 
fluorescence intensity is linear we created two standard curves: 
one for the fluorescence intensity obtained from increasing 
amounts of DAF-2T (Fig. 2A) and another one correlating 
increasing NO concentrations (liberated by the NO donor NOC-
9 (22) in the presence of EA.hy 926 cells) to the fluorescence 
intensity measured after addition of 0.1 µM DAF-2 (Fig. 2B). As 
shown in Figure 2, employing up to 100 nM NOC-9 
(corresponding to 200 nM NO) the correlation between NO 
concentration and fluorescence intensity is linear (r2 = 0.997). In 
addition, the fluorescence intensity obtained from 100 nM NOC-
9 (200 nM NO) consumed only 0.44 nM DAF-2 which is less 
than 1% of the employed DAF-2. These results show that 0.1 µM 
DAF-2 is sufficient and not rate-limiting for the detection of up 
to 200 nM NO. In addition, under these conditions the auto-
fluorescence background stays nearly constant (> 99% DAF-2 is 
not consumed), which allows to subtract it from the measured 
total fluorescence. 
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Fig. 1: The difference in measured fluorescence intensity of DAF-2 alone or after 
reaction with NO released from endothelial cells becomes more significant with 
lower DAF-2 concentrations. Blank vials (white bars) or EA.hy 926 cells (black 
bars) were incubated with PBS supplemented with 100 µM of L-arginine for 5 
min at 37°C in the dark. Then DAF-2 at the indicated concentrations and the 
calcium ionophore A23187 (1 µM) were added. 5 min later. The fluorescence of 
the supernatants was measured as described in Materials and Methods. All data are 
mean ± S.D. (n = 2 in triplicate). Differences between means were analyzed using Räthel et al.    
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Student’s t-test. *P< 0.05; **P< 0.01. 
 
Ap p l yi n g th i s me th o d w e w e re ab l e to  sh o w  th at i t i s i n de e d  
suitable to detect small amounts of NO released from human 
endothelial cells (19, 23).  
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Fig. 2: A: Dependency of fluorescence intensity on the concentration of DAF-2T. 
DAF-2T was added to PBS in the concentrations as indicated and fluorescence of 
the solution was determined. (n=4) Y=59.71x+0.466; R2=0.9997. B: Dependency 
of the fluorescence intensity on the concentration of NO in the presence of cells. 
EA.hy926 cells were grown to confluence, washed with PBS and incubated for 5 
min in PBS supplemented with 100 µM L-arginine. Then 0.1 µM of DAF-2 and 
the indicated concentrations of the NO-donor NOC-9 were added. After 5 min 
reaction time in the dark at 37°C the fluorescence was measured. Auto-
fluorescence of DAF-2 in cell supernatants without NOC-9 was subtracted. 
(n=6). Y=0.2714x-0.2947; R2= 0.9981 
 
To proof that the used method specifically detects cell derived 
NO, we employed the NOS inhibitor L-NMMA. The inhibitor 
completely abolished the 2.5-fold increase of NO release from 
EA.hy926 cells in response to PMA (2 nM) in the absence and in 
the presence of the calcium ionophore A23187 (19). 
 
EA.hy926 is a hybridoma cell line derived by fusing primary 
human umbilical vein endothelial cells (HUVEC) with the 
permanent human cell line A549 (lung carcinoma). In order to 
verify that NO released from primary endothelial cells can also 
be quantified by DAF-2 we employed HUVEC in a recent study 
showing that a red wine polyphenol extract induces active eNOS 
in human endothelial cells (23). The data obtained from 
EA.hy926 and HUVEC were very well comparable. The NO 
production in both cell types could be inhibited by NG-amino-L-
arginine. 
 
Since so far the data collected in our laboratory from the 
modified DAF-2 method were limited to pharmacological agents, 
a future aim will be to examine the value of the method with 
respect to endothelial cells stimulated with insulin (24-26) or 
bradykinin (27, 28) as physiological stimuli. 
 
What are the limitations and pitfalls of this 
method? 
 
The following things should be considered: First, the number of 
cells delivering NO should not be chosen too small in relation to 
the volume of supernatant. Otherwise, the differences in NO 
concentrations of e.g. activated or non-activated cells may not be 
detectable. We found confluent cells in a 6-well plate with a 2 ml 
supernatant workable. 2 ml supernatant is enough for a 
convenient measurement in a standard cuvette.  
 
Another limitation is given by the spectrofluorimeter itself. In 
order to measure NO from low-output systems the sensitivity 
and resolution of the spectrofluorimeter has to be adequately 
high. We use a Shimadzu RF-1501 with the sensitivity 
programmed on high. Since the excitation maximum of DAF-2T 
is at 495 nm and the emission maximum at 515 nm, in 
instruments with low resolutions, the shoulder of the peak caused 
by Rayleigh light scatter (495 nm) may overlap with the 
maximum of the DAF-2T emission peak (515 nm) (Fig. 3A). To 
improve the resolution it is possible to chose a smaller slit width 
for the excitation beam (e.g. 5 nm) or a lower excitation 
wavelength. The scattered light peak then shifts to the respective 
wavelength, too. However, as can be seen in Figure 3A, leaving 
the DAF-2T absorbance maximum (495 nm) for excitation the 
measured emission fluorescence intensity becomes smaller and 
thus the detection limit for NO increases. Thus, it is necessary to 
find an excitation wavelength which fits both, a) a satisfactory 
resolution of the scattered light peak from the DAF-2T emission 
light peak and b) an acceptable emission intensity.  
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Fig. 3: A: Spectra of DAF-2T obtained by excitating at different wavelength (480-
495 nm): Cells were grown to confluence and stimulated with PMA 2 nM for 18 h. 
Then, cells were washed with PBS and supplemented with L-arginine (100 µM) 
and kept in the dark (5 min, 37°C). Thereafter, DAF-2 (0.1 µM) and A23187 (1 
µM) were added for 5 min in the dark at 37°C. Spectra of supernatants were 
measured at different excitation wavelength. B: Spectra were measured at an Räthel et al.    
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excitation wavelength of 495 nm with different concentrations of NO liberated 
from the NO-donor NOC-9. 
 
In order to demonstrate that – in our system - the DAF-2T 
fluorescence is detectable independently of the Rayleigh scattered 
excitation light peak even at an excitation wave length of 495 nm 
we measured DAF-2T spectra obtained from different 
concentrations of NO (0.01-20 µM) liberated by the NO-donor 
NOC-9. Figure 3B demonstrates that the fluorescence intensity 
measured at 515 nm (λex 495 nm) decreased with the NO 
concentration to background levels. This shows that the 
measured fluorescence intensity is caused solely by DAF-2T and 
not by Rayleigh scattering of the excitation light. Such validation 
experiments have to be performed for every spectrofluorimeter 
before starting experiments. 
 
A further problem that limits NO quantification in general is the 
concurrent presence of reactive oxygen species (ROS). In the 
presence of NO ROS cause the generation of peroxynitrite which 
does not react with DAF-2 (14). One conceivable way to cope 
w i th  th i s p ro b l em i s  to  sc av a n ge R O S , s uc h  as s up e ro xi d e o r  
peroxide (29). As superoxide scavanger we used PEG:SOD (100 
U/ml, 250 U/ml, 500 U/ml, 20 h preincubation) and the cell-
permeable SOD mimic Mn TBAP (100 µM, 300 µM, 24 h 
preincubation) (30, 31). PEG:SOD was not able to enhance the 
measured fluorescence intensity compared to controls without 
SOD (data not shown). Also Mn TBAB failed to enhance 
measured fluorescence intensity of supernatants of EA.hy 926 
cells and HUVECs after PMA (2 nM, 20 h) stimulation 
compared to controls without Mn TBAP (data not shown). 
Moreover, Mn TBAP itself shows fluorescence activity at 515 nm 
clearly limiting its use. In order to reduce peroxide we also added 
purified horseradish peroxidase (HRP) to our system (10 U/ml, 
100 U/ml, 500 U/ml, 10 min preincubation). However, HRP 
itself, an iron-containing hem protein, seems to react with NO or 
other compounds from endothelial cells resulting in a highly 
fluorescent product (data not shown). Thus, neither PEG:SOD 
nor Mn TBAP or HRP seem to be a suitable tool to increase free 
and thus detectable levels of NO in the DAF-2 assay. Another 
approach would be the application of catalase. However, catalase 
is also an iron-containing heme protein probably reacting with 
NO. Thus, more thorough investigations are needed to find the 
right compound, concentration and incubation conditions to 
definitely show whether ROS scavenging will improve our test 
system by increasing the output of free NO. 
 
Considering the fact that DAF-2 does not react with NO itself 
but with an active intermediate formed during the oxidation of 
NO in the presence of O2, the method is prone to errors caused 
by redox-active compounds (32). In fact, we did not see 
enhanced amounts of NO in supernatants of cells treated with 
ascorbic acid (33) although we detected a clear increase in L-
citrulline when employing ascorbic acid to a L-arginine/L-
citrulline conversion assay as described (23) (data not shown). L-
citrulline emerges in eqimolar concentrations to NO as a result of 
the NOS-catalyzed oxidation of a guanidino nitrogen of L-
arginine. This suggests that ascorbic acid increases eNOS activity 
in our cell system. The increase in NO release, however, cannot 
be detected by DAF-2. It seems likely that reducing compounds, 
such as ascorbic acid, may prevent the formation of the DAF-2-
reactive oxidation product of NO and, thus, lead to false negative 
results. Redox-active compounds should, therefore, be evaluated 
by at least one additional technique or assay system, such as the 
L-arginine/L-citrulline conversion assay (23). 
 
A further point that needs to be considered is a putative auto-
fluorescence of test compounds detectable at 515 nm. In order to 
avoid false positive results it is necessary to check this eventuality 
for every substance employed to this assay. Although cells are 
washed before DAF-2 addition and NO measurement there may 
be fluorescent remains that may influence the measured DAF-2T 
fluorescence. We ourselves tried to cope with this phenomenon 
several times by intensive cell washing, however, in vain. We, 
therefore, conclude that substances with an auto-fluorescence 
around 515 nm are not applicable in the DAF-2 assay system. 
 
Finally, some attention should be paid to the fact that the 
concentrations of divalent cations like Ca2+ or Mg2+ affect the 
fluorescence of DAF-2 (34). However, extracellular 
concentrations of ions are not subject to high fluctuations in in 
vitro assay systems. Thus, the measurement of extracellular NO 
should not be susceptible to this phenomenon.  
 
At last, it is strictly required to work in a darkened room when 
handling DAF-2 and DAF-2T samples. We found a decrease in 
fluorescence of samples if they were not protected from light 
even for a few minutes. This bleaching event occurs also when 
samples are measured more than once. Räthel et al.    
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PROTOCOLS 
 
Cell culture (optimized for EA.hy 926 endothelial cells): 
 
Grow cells in Dulbeco’s Modified Eagle’s Medium (DMEM) without phenol red containing 584 mg/ml L-glutamine (Bio Whittaker 
Europe, Belgium) supplemented with 100 U/ml benzylpenicillin, 100 µg/ml streptomycin (PAN Biotech, Germany), HAT supplement 
(100 µM hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine) and 10% fetal bovine serum (Life Technologies, Germany). Seed cells in 
a density of 4 x 106 cells per well in 6-well plates. Stimulate cells at day 3, when they just reach confluence. Duration of stimulation 
depends on substances and experimental settings. If test compounds are dissolved in DMSO the final concentration should not exceed 
0.1%. 
 
Preparations 
 
A: Prepare the following solutions: 
1.  L-arginine stock solution:  100 mM L-arginine in H2O (0.021 g/ml) 
2.  A23187 stock solution:  10 mM A23187 in DMSO (1 mg in 191 µl of DMSO), store solution at -20°C 
3.  DAF-2 stock solution:  Shipped 5 mM in DMSO, aliquot and freeze at -80°C 
4. PBS+Ca2+: KH2PO4  1.47 mM  0.4 g/2 L 
   Na2HPO4 • 7 H2O  9.57 mM  5.13 g/2 L 
    NaCl  137.00 mM  16.00 g/2 L 
   MgSO4 • 7 H2O  0.49 mM  0.24 g/2 L 
    KCl  2.68 mM  0.40 g/2 L 
   CaCl2 • 2 H2O  0.90 mM  0.24 g/2 L 
Solve CaCl2 in 1 L and all other components in another 1 L H2O. Mix both solutions carefully and adjust pH to 
7.4. The pH has to be strictly regarded since the fluorescence of the DAF derivatives is pH-dependent. 
 
B. Before starting the assay 
 
1.  Warm up the water bath and a drying chamber/incubator to 37°C. 
2.  Prepare a PBS+Ca2+ that is supplemented with 100 µM L-arginine by adding the L-arginine stock solution (100 mM) 1:1000. Warm 
up the solution in a 37°C water bath. 
3.  Dilute your A23187 stock solution (10 mM) 1:5 in DMSO. 
4.  Dilute your DAF-2 stock solution (5 mM) 1:250 in PBS+Ca2+supplemented with L-arginine (as prepared under 2.) and keep it on 
ice in a light-protected box until use. 
5.  Start your spectrofluorimeter software. 
6.  Bring cuvettes, rinsing water and a waste jar to your spectrofluorimeter in a dark room to prepare your samples. 
 
Assay performance 
 
Please note: perform all operations with DAF-2 in a darkened room! Make sure that samples are protected from light while being 
transported to the spectrofluorimeter! 
 
1.  Remove cell supernatants and wash cells twice in 1 ml PBS+Ca2+. 
2.  Incubate cells with 2 ml PBS+Ca2+ supplemented with L-arginine for 5 min at 37°C to let them equilibrate with a defined 
concentration of L-arginine. 
3.  Add 1 µl of the diluted A23187 solution as prepared under B,3 (final concentration of 1 µM). 
4.  Add 10 µl of the diluted DAF-2 solution as prepared under B,4 (final concentration of 0.1 µM). 
5.  Incubate cells again for 5 min at 37°C in the dark. NO released during this time will react with DAF-2 to DAF-2T. 
6. Transfer  cell  supernatants into 2 ml plastic caps quickly to assure that the reaction time for all samples will be the same. 
7.  Measure the fluorescence of cell supernatants in a standard cuvette as fast as possible. Make sure that all samples are well protected 
from light until measurement is done. Measurement should be done at an excitation wavelength between 490 and 495 nm, as 
individually validated, and an emission wavelength at 515 nm. Slit width for emission and excitation: 10 nm. Sensitivity should be 
chosen as high as possible. 
8.  Measure also wells without cells in order to calculate the DAF-2 auto-fluorescence. 